Q
Qianglian Zhichuang (Beijing) Technology
The first high-tech company in China to focus on the pain points of cerebrovascular disease treatment
About Qianglian Zhichuang (Beijing) Technology
Established in September 2016 by founder and chairwoman Qin嵐, Qianglian Zhichuang (Beijing) Technology Co., Ltd. is a high-tech enterprise focused on developing intelligent diagnosis and treatment solutions for cerebrovascular diseases. The company's inception was driven by the significant challenges and high skill requirements of neuro-interventional surgery for conditions like brain aneurysms. Recognizing the lack of a comprehensive Chinese cerebrovascular disease database, Qin岚 led her team to build one from the ground up by collaborating with national neurological hospitals, which now underpins their product development.
The company's business is centered on applying artificial intelligence to improve the entire workflow of cerebrovascular disease management, from screening and diagnosis to treatment and follow-up. Its target market includes not only the top-tier hospitals in major cities but also a vast network of thousands of local and community-level hospitals where advanced surgical expertise may be less accessible. The business model involves providing integrated solutions that combine software, hardware, and associated medical consumables. A significant milestone was achieved in October 2022, when its "Intracranial Aneurysm Surgical Planning Software" received NMPA approval as an innovative medical device. The firm has successfully secured multiple rounds of funding, including a Series C round led by Sequoia China in January 2022 and a D+ round in 2024, to facilitate its transition from research and development to commercialization and market expansion.
Qianglian Zhichuang's core offering is an AI-driven, integrated solution for intracranial aneurysm surgery. This platform includes the UKnow® Intracranial Aneurysm Surgical Planning Software, which assists surgeons by rendering 3D images from patient scans (DSA, CTA, MRA), allowing for precise measurement and visualization of the aneurysm. A key benefit of the software is its ability to help plan the micro-catheter's path and shape for delivering coils, which can increase the first-pass success rate, shorten procedure times, and reduce radiation exposure for both doctor and patient. This AI-powered system aims to standardize and simplify complex surgical procedures, shortening the learning curve for less experienced surgeons. The full solution comprises the intelligent software, an automated hardware terminal (UMate™), and related consumables, creating a comprehensive system that assists surgeons from pre-operative planning to critical surgical steps.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 54.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Oct 2024 | $28M | $110M | Yizhuang State Investment · Shunxi Private Equity Fund Management | ↗ |
| SERIES DOther financing | Dec 2023 | $14M | $55M | Yantai Biomedical Fund of Funds | ↗ |
Growth signals
Latest recorded traffic for Qianglian Zhichuang (Beijing) Technology is 20 monthly website visits, down 86.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qianglian Zhichuang (Beijing) Technology in the Dongcheng District ecosystem
The Qianglian Zhichuang (Beijing) Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- AFAnlong Fund
Series A3 investors entered at this stage
Lenovo Capital and Incubator Group (LCIG)- K2K2VC
Sunland fund
Series B and later5 investors entered at this stage
Sequoia- PCPoly Capital
- YFYantai Biomedical Fund of Funds
- SMShunxi Private Equity Fund Management
- YIYizhuang State Investment
Other known investors2 additional known investors
Capital University of Medical Sciences
Fudan University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qianglian Zhichuang (Beijing) Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qianglian Zhichuang (Beijing) Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










